dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Αντινεοπλασματικοί παράγοντες - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. Βλ. Ενότητες 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
levo-4 oral.sol 25mcg/5ml
rafarm a.e.b.e. ΚΟΡΙΝΘΟΥ 12, 15451 Ν. ΨΥΧΙΚΟ 6776550, 6747086 - levothyroxine sodium - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 25mcg/5ml - levothyroxine sodium 25mcg - levothyroxine sodium
levo-4 oral.sol 50mcg/5ml
rafarm a.e.b.e. ΚΟΡΙΝΘΟΥ 12, 15451 Ν. ΨΥΧΙΚΟ 6776550, 6747086 - levothyroxine sodium - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 50mcg/5ml - levothyroxine sodium 50mcg - levothyroxine sodium
levo-4 oral.sol 100mcg/5ml
rafarm a.e.b.e. ΚΟΡΙΝΘΟΥ 12, 15451 Ν. ΨΥΧΙΚΟ 6776550, 6747086 - levothyroxine sodium - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 100mcg/5ml - levothyroxine sodium 100mcg - levothyroxine sodium
rifaren 300mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - rifampicin - capsule,hard - 300mg - rifampicin (0013292461) 300.000000000000mg - rifampicin
rifaren 150mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - rifampicin - capsule,hard - 150mg - rifampicin (0013292461) 150.000000000000mg - rifampicin
dasatinib/faran f.c.tab 80mg/tab
ΦΑΡΑΝ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ Δ.Τ. ΦΑΡΑΝ Α.Β.Ε.Ε. Αχαίας 5 & Τροιζηνίας, 145 64 Ν. Κηφισιά 210.6254175 - dasatinib - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 80mg/tab - dasatinib 80mg - dasatinib
dasatinib/faran f.c.tab 140mg/tab
ΦΑΡΑΝ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ Δ.Τ. ΦΑΡΑΝ Α.Β.Ε.Ε. Αχαίας 5 & Τροιζηνίας, 145 64 Ν. Κηφισιά 210.6254175 - dasatinib - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 140mg/tab - dasatinib 140mg - dasatinib
dasatinib/faran f.c.tab 50mg/tab
ΦΑΡΑΝ ΑΝΩΝΥΜΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΠΑΡΑΓΩΓΗΣ ΚΑΙ ΕΜΠΟΡΙΑΣ ΦΑΡΜΑΚΩΝ Δ.Τ. ΦΑΡΑΝ Α.Β.Ε.Ε. Αχαίας 5 & Τροιζηνίας, 145 64 Ν. Κηφισιά 210.6254175 - dasatinib - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 50mg/tab - dasatinib 50mg - dasatinib